Key Drivers
- Robust margins
- High leverage
- Large intangibles
AIAI Summary
BDx is shifting from a predictable consumables cash machine to an execution‑dependent growth pivot—investors should demand clear, multi‑quarter margin recovery, measurable deleveraging (net leverage <~2.5x) and commercial traction on biologic drug‑delivery/Pyxis/approved devices as prerequisites for the current premium valuation, otherwise tariff/remediation, integration or goodwill risks could trigger meaningful downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Robust margins
- •High leverage
- •Large intangibles
BDX shows strong gross and EBITDA margins with solid free cash flow but is constrained by high leverage, low ROE, large intangibles and rich valuation.
Price Behavior
Key Price Behavior Insights:
- •Below last-month average
- •Sharp recent decline
- •Support cluster near $154
BDX is in a short-term downtrend—trading ~8.4% below its last-month average (~$168.30) after a ~16.3% drop from the late‑February high, with immediate support near $154.13 and resistance at $175–$184.
~16.3% drop from $184.21 to $154.13 over the period, implying elevated short-term volatility
Sentiment & News
Key News Insights:
- •Regulatory approvals
- •$2B buybacks
- •Short-term weakness
Becton Dickinson landed multiple FDA/CE approvals and a new urine kit to boost clinical efficiency while executing up to $2B in note repurchases—yet shares have lagged since the latest earnings.
Regulatory wins and product rollouts should support long-term revenue and clinical adoption, but near-term stock volatility may persist as investors digest execution and debt-reduction impact
Similar Companies in Healthcare
Other companies in the same sector with AI ratings